MAAT PHARMA | Finanzwire

Basculer en Français

10598	Companies
224804	Keywords
153540	Articles
118955	Press releases

Home
Companies
MAAT PHARMA

BRIEF

published on 06/11/2026 at 13:12, 7 days 13 hours ago

MaaT Pharma Faces Regulatory Hurdles with MaaT013 Approval

MaaT Pharma CHMP Opinion Acute GvHD MaaT013 Approval Regulatory Hurdles
PRESS RELEASE

published on 06/11/2026 at 13:07, 7 days 13 hours ago

Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review
First Berlin Equity Research updates recommendation on MaaT Pharma SACA as CHMP issues 'negative trend' opinion on MAA for MaaT013 in acute GvHD, triggering appeal process for potential outcome in September/October 2026

CHMP MaaT Pharma SACA Acute GvHD Negative Trend MAA
BRIEF

published on 05/26/2026 at 19:05, 23 days 7 hours ago

MaaT Pharma Activity and Results Update for Q1 2026

Treasury MaaT Pharma Q1 2026 Results Xervyteg® CHAMP
BRIEF

published on 05/26/2026 at 19:05, 23 days 7 hours ago

MaaT Pharma Faces Challenges in Q1 2026

MaaT Pharma Early Access Program Q1 2026 Financial Results EMA Marketing Challenges Clinical Trials Update
PRESS RELEASE

published on 05/26/2026 at 19:00, 23 days 7 hours ago

Inside Information / Other news releases
MaaT Pharma provides a business update and reports financial results for the first quarter of 2026, highlighting regulatory activities and cash position. Lyon, France

Financial Results Business Update Cash Position MaaT Pharma Regulatory Activities
BRIEF

published on 05/20/2026 at 20:50, 29 days 5 hours ago

MAAT Pharma Faces Setback in Authorization for MaaT013

Biotech MaaT Pharma EMA MaaT013 AGvHD
PRESS RELEASE

published on 05/20/2026 at 20:45, 29 days 5 hours ago

Inside Information / Other news releases
MaaT Pharma receives a 'negative trend' opinion from CHMP for their Marketing Authorization Application of MaaT013 (Xervyteg) in acute Graft-versus-Host Disease treatment. Company plans re-examination procedure

MaaT Pharma CHMP Marketing Authorization Negative Trend Re-examination
BRIEF

published on 04/21/2026 at 15:14, 1 month 27 days ago

MaaT Pharma SACA Maintains Buy Rating with Stable Financial Outlook

Financial Performance BUY Rating Pipeline Development MaaT Pharma Investment Case
PRESS RELEASE

published on 04/21/2026 at 15:09, 1 month 27 days ago

Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research reaffirms Buy rating for MaaT Pharma SACA with a target price of €17 following FY25 results and pipeline update. No changes to core investment case

First Berlin Equity Research BUY Rating MaaT Pharma SACA FY25 Results €17 Target Price
BRIEF

published on 04/01/2026 at 07:35, 2 months 17 days ago

MaaT Pharma Presents CHRONOS Study Results on Third-Line Acute GvHD

MaaT Pharma Regulatory Review CHRONOS Study Acute GvHD Third-line Therapy

1 2 ... 6

Accesswire

Published on 06/19/2026 at 01:20, 1 hour ago

American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 1 hour 13 minutes ago

Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/19/2026 at 00:55, 1 hour 25 minutes ago

INEO Announces Grant of Stock Options
Published on 06/19/2026 at 00:00, 2 hours 20 minutes ago

Redwood AI Announces Initiation of Chemical Risk Assessment Module
Published on 06/18/2026 at 23:55, 2 hours 25 minutes ago

Relevant Gold Announces Results of Annual and Special General Meeting and Welcomes New Board Member

View all ACCESSWIRE

EQS Group

Published on 06/19/2026 at 01:15, 1 hour 4 minutes ago

UV Laser Technology Gains Momentum in Europe for Clean, Cold Marking and High-Precision Engraving
Published on 06/18/2026 at 22:35, 3 hours 44 minutes ago

Bitmine Immersion Technologies Announces Cash Dividend of $0.1056 per Share of 9.50% Series A Perpetual Preferred Stock
Published on 06/18/2026 at 22:00, 4 hours 20 minutes ago

Blue Cap AG: Closing of the Acquisition of Janoschka AG Successfully Completed
Published on 06/18/2026 at 18:55, 7 hours 25 minutes ago

Holding(s) in Company
Published on 06/18/2026 at 18:55, 7 hours 25 minutes ago

Holding(s) in Company

Les Echos

Published on 06/18/2026 at 18:00, 8 hours 20 minutes ago

Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 8 hours 35 minutes ago

EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 8 hours 41 minutes ago

Statement of transactions in own shares from June 8, 2026 to June 12, 2026
Published on 06/18/2026 at 13:00, 13 hours 20 minutes ago

Edenred statement
Published on 06/18/2026 at 09:06, 17 hours 14 minutes ago

Eiffage, member of the NSORe joint venture, wins the contract for a converter station for the NSC2 offshore grid connection project in Germany

View all LES ECHOS COMFI WIRE